This New DNA Vaccine Could Change the Game for Prostate Cancer — Are You at Risk?

A recent Phase 2 clinical trial has shed light on an innovative approach to treating metastatic castration-resistant prostate cancer (mCRPC) by combining the established immunotherapy Pembrolizumab with DNA vaccines. This trial posed a crucial question: can active immune priming using DNA vaccines enhance Pembrolizumab's effectiveness in a disease often resistant to conventional checkpoint blockade therapies?

Rather than solely inhibiting the PD-1 pathway, researchers combined Pembrolizumab with tumor-specific vaccines targeting prostate antigens, aiming to generate and amplify a T-cell-mediated anti-tumor response. The findings signal not only biological efficacy but also highlight the need for optimization in this therapeutic strategy.

The randomized trial enrolled 60 patients with mCRPC and evaluated whether broadening tumor-specific T-cell activation could improve the efficacy of Pembrolizumab. Participants were assigned to one of two strategies: a single-antigen approach using the pTVG-HP vaccine targeting prostatic acid phosphatase (PAP) combined with Pembrolizumab, or a dual-antigen approach that included the pTVG-HP vaccine and an additional pTVG-AR vaccine targeting the androgen receptor, alongside Pembrolizumab.

The primary endpoint was 6-month progression-free survival (PFS), with secondary endpoints including overall survival (OS), prostate-specific antigen (PSA) response, objective response rate (ORR), safety, and immunologic correlates. Patients received DNA vaccines on days 1 and 8 of a 3-week cycle, with Pembrolizumab administered on day 1. After six months, patients continued with Pembrolizumab maintenance and some received booster vaccinations upon PSA progression.

Results indicated that while both treatment arms demonstrated clinically meaningful activity, the advantage stemmed more from the immune priming strategy rather than the complexity of antigen targets. The median time to disease progression was approximately 24 weeks for both groups, with 6-month PFS rates of 51% in the single-vaccine arm and 45% in the dual-vaccine arm. This suggests that adding a second antigen did not significantly enhance the ability to delay disease progression.

6-month progression-free survival (PFS):

• 51% (single vaccine)
• 45% (dual vaccine)

A numerical difference in overall survival was observed, with median OS showing approximately 29.9 months for the single-vaccine approach and 44.7 months for the dual-vaccine arm. However, these results did not reach statistical significance, warranting cautious interpretation.

Median overall survival (OS):

• ~29.9 months (single vaccine)
• ~44.7 months (dual vaccine)

Despite the limited sample size and potential baseline differences between groups, the study showed promising signs of antitumor activity. Notably, PSA reductions were observed in about 32% of patients, and a 50% or greater decline was observed in around 20%. The objective response rate was approximately 30% in patients with measurable disease—significant findings for a patient population not selected for traditional immunotherapy-responsive biomarkers.

PSA responses:

• Any decline: ~32%
• ≥50% decline: ~20%

Objective response rate (ORR):

• ~30% in patients with measurable disease

Some patients even achieved durable disease control, remaining progression-free beyond six months. Interestingly, those who received booster vaccinations at PSA progression often experienced renewed declines in PSA levels, indicating that the immune response could be reactivated with continued antigen exposure. About 28% of patients remained progression-free beyond six months, and evidence of response reactivation was noted with booster vaccinations.

Durable benefit:

• ~28% progression-free beyond 6 months
• Evidence of response reactivation with booster vaccination

In terms of safety, the combination treatment was generally well tolerated. Most adverse events were low-grade, although the dual-vaccine approach was linked to a modest increase in immune-related toxicity. This included signals in tissues that physiologically express the androgen receptor, raising concerns about potential complications.

Immunologic analyses revealed an unexpected insight: while clinical activity was evident, there was limited detectable peripheral T-cell activation and classic cytokine signatures were not consistently elevated. This suggests that the therapeutic effect may depend more on local tumor immune dynamics than merely on the magnitude of systemic immune activation.

Looking at the broader context, median overall survival in past mCRPC trials has typically ranged from 20 to 30 months, while PD-1 monotherapy has shown minimal activity outside of biomarker-selected populations. In contrast, this trial reported a median OS of approximately 33.6 months, alongside noteworthy PSA responses and an objective response rate, hinting at a genuine biological effect arising from the combination of immune priming and checkpoint inhibition.

However, several limitations are important to note: the small sample size of 60 limits statistical power, there was no true control arm to isolate the vaccine effect, and the study was not powered to definitively assess OS outcomes. Additionally, patient heterogeneity and variations in prior treatments may have influenced the results, and the timing of vaccinations could affect immune activation strength and durability.

Key takeaways include:

• Immunotherapy in prostate cancer is limited not by Pembrolizumab itself, but by insufficient immune activation.
• Combining DNA vaccines with PD-1 blockade can generate meaningful clinical activity in mCRPC.
• Using multiple antigen targets does not improve efficacy and may increase toxicity.
• PSA responses and ORR signals indicate that this treatment approach is not trivial.
• Success in “cold” tumors hinges on effective immune priming, rather than just checkpoint inhibition.

The ongoing exploration of immune priming strategies in prostate cancer may ultimately pave the way for more effective treatments, offering hope to patients facing this challenging diagnosis.